Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
18 nov. 2024 11h00 HE
|
Siren Biotechnology, Inc.
Siren Biotechnology reveals SRN-101 as lead asset for high-grade gliomas with both Orphan Drug and Rare Pediatric Disease Designations from the FDA
Vivet Therapeutics to Present Key Findings on its Gene Therapy Program for Cerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting
14 nov. 2024 03h30 HE
|
Vivet Therapeutics
Vivet Therapeutics to Present Key Findings on its Gene Therapy Program for Cerebrotendinous Xanthomatosis at the American Association for the Study of Liver Diseases Annual Meeting Gene therapy...
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
12 nov. 2024 16h05 HE
|
Fractyl Health, Inc.
REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025
Ocugen Provides Business Update with Third Quarter 2024 Financial Results
08 nov. 2024 06h45 HE
|
Ocugen
Subsequent to quarter-end, closed $30 million in debt financingOCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to complete enrollment in 1H2025OCU410 is currently in...
Cell And Gene Therapy Market Size to Worth USD 190.82 Billion by 2033 | Straits Research
07 nov. 2024 09h30 HE
|
Straits Research Private Limited - Garner Insights
New York, United States , Nov. 07, 2024 (GLOBE NEWSWIRE) -- “Cell therapy” refers to the process of administering live cells to patients with the purpose of treating various diseases. Both...
Ocugen Secures $30 Million in Debt Funding
07 nov. 2024 06h30 HE
|
Ocugen
MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
05 nov. 2024 07h05 HE
|
uniQure Inc.
~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington’s disease ~ ~...
Cell and Gene Therapy CRO Market Research Trends and Global Forecasts, 2024-2035: Over 105 CROs Drive Innovation, with 80% Ensuring Comprehensive Support from R&D to Clinical Trials
04 nov. 2024 05h40 HE
|
Research and Markets
Dublin, Nov. 04, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification,...
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference
30 oct. 2024 06h14 HE
|
Lexeo Therapeutics
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's
Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
28 oct. 2024 07h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024